Perimenopause, the hormonally turbulent years leading up to menopause, remains one of medicine's biggest blind spots. While menopause itself is easy to identify after the fact (12 consecutive months without a period), perimenopause happens in real time with no clear diagnostic test or biomarker to guide treatment. This creates a troubling gap: the years when symptoms are most debilitating are the same years when clinicians have the least research-based guidance on how to help. Rachel Pope, a gynaecologist at Case Western Reserve University in Cleveland, Ohio, discovered this problem firsthand when she asked her three older sisters who they would turn to for help with sleep problems, thinning hair, low libido, and hot flushes. "They said they would see a GP for some issues, a gynaecologist or dermatologist for others," Pope explained. "I realized they were not connecting that all of these symptoms are coming from one collective situation, which is perimenopause". This fragmented approach reflects a deeper scientific reality: most menopause research has focused on the years after periods stop, leaving perimenopause largely unstudied. Why Is Perimenopause So Hard to Study and Treat? The challenge lies in perimenopause's unpredictability. Unlike menopause, which can be confirmed retroactively, perimenopause is a moving target. Hormone levels fluctuate wildly from day to day, and symptoms vary dramatically from person to person. Susan Davis, an endocrinologist at Monash University in Melbourne, Australia, who has studied menopause for decades, put it plainly: "We're not good at treating perimenopause because we don't completely understand it". This knowledge gap has real consequences. When clinicians do prescribe treatment, they often rely on approaches developed for postmenopausal women, not those still experiencing hormonal fluctuations. Menopausal hormone therapy (MHT) and hormonal contraceptives are designed to stabilize hormone levels by supplementing declining oestrogen and progesterone. But in perimenopause, when the body is still producing variable amounts of its own hormones, adding more can backfire. "In some cases, giving more oestrogen can make things worse," Davis noted, because women who are perimenopausal may "bleed all over the place" when hormone levels spike unpredictably. What Treatment Options Exist, and What Are Their Limitations? The absence of clear perimenopause research has created a vacuum that some providers have filled with unproven treatments. Hormone pellets implanted under the skin are marketed as quick fixes, with risks often downplayed. Testosterone, another hormone that declines with age, is used by some women during perimenopause and menopause to address low libido, brain fog, or low energy. However, few studies have evaluated the long-term safety of testosterone for menopause symptoms, and physician guidelines advise against using it as a first-line treatment. For those who prefer or need non-hormonal options, alternatives exist but are limited. Antidepressants and gabapentinoids can reduce hot flushes and night sweats through different biological pathways. In May 2023, the FDA approved fezolinetant, the first non-hormonal treatment specifically designed to target hot flushes directly. Yet even these options lack the long-term safety data that women deserve. How to Navigate Perimenopause Symptoms: What Experts Recommend - Seek a specialist with perimenopause expertise: Look for healthcare providers certified in menopause treatment. Between 2022 and 2024, there was a fivefold increase in people applying to take the certification exam of the Menopause Society, suggesting growing expertise in this area. - Track your symptoms and hormone patterns: Since perimenopause is highly individual, keeping a detailed log of when symptoms occur, their severity, and any patterns can help your provider tailor treatment rather than relying on one-size-fits-all approaches. - Discuss both hormonal and non-hormonal options: Work with your provider to weigh the benefits and risks of MHT, hormonal contraceptives, antidepressants, gabapentinoids, or newer options like fezolinetant based on your specific symptoms and health history. - Ask about long-term effects: Be honest with your provider about what you want to know. As Pope acknowledged, "I can tell you these treatments are helping my patients relieve their symptoms. But I can't tell you from our current data what that means several decades from now". The perimenopause research gap extends beyond treatment options. Major medical societies now agree that for women experiencing symptoms around the typical age of menopause, hormone therapy's benefits outweigh its risks, based on reanalyses of the landmark Women's Health Initiative study from 2002. Yet the long-term health benefits and risks of starting MHT specifically in perimenopause remain understudied. This uncertainty leaves women and their doctors navigating treatment decisions with incomplete information. The broader context makes this gap even more troubling. Menopause research globally is underfunded relative to its impact on half of humanity. The US National Institutes of Health allocated $56 million to menopause studies in 2023, projected to increase to $58 million in 2024, and only established a dedicated menopause research category in 2023. Meanwhile, conditions that predominantly affect men receive significantly more research funding. Horizon Europe, the world's largest multinational research-funding programme, has not created a separate menopause category, instead lumping it into a general "health" portfolio. Until perimenopause research catches up with clinical need, women experiencing the most disruptive years of the menopause transition will continue to navigate fragmented care and unproven treatments. The solution requires both increased research funding and a shift in how the medical community approaches this life stage, recognizing perimenopause not as a minor prelude to menopause, but as a distinct clinical challenge worthy of its own scientific attention.
